Clostridium Difficile Infection Recurrence
4
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
On Market (1)
Approved therapies currently available
M&
Competitive Landscape
3 companies ranked by most advanced pipeline stage
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Merck & Co.bezlotoxumab
Ferring PharmaceuticalsRBX2660
Vedanta BiosciencesVE303
Clinical Trials (3)
Total enrollment: 124 patients across 3 trials
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
Start: Jun 2019Est. completion: Nov 20214 patients
Phase 4Completed
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
Start: Apr 2023Est. completion: Jan 202541 patients
Phase 3Completed
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Start: Feb 2019Est. completion: Sep 202179 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space